Screening, evaluation or production method of sodium lauryl sulfate as a raw material for pharmaceutical preparations or preparations containing the same

By pretreating and testing sodium dodecyl sulfate under accelerated conditions, low impurities of drug preparation raw materials were screened, and the problem of small mass differences in drug preparations affected stability and dissolution was solved, and high quality and Manufacturing of high stability pharmaceutical preparations.

CN114786727BActive Publication Date: 2024-11-08CHUGAI PHARMA CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202080089304.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-27
Filing Date
2020-12-25
Publication Date
2024-11-08
Estimated Expiration
2040-12-25

AI Technical Summary

Technical Problem

It is difficult for the prior art to effectively detect and screen slight mass differences in pharmaceutical preparations of sodium dodecyl sulfate, which affects the stability and dissolution of the preparation.

Method used

Sodium dodecyl sulfate was pretreated under accelerated conditions (65-75°C, humidity below 79% RH), and impurities were detected by powder X-ray diffraction, ion exchange chromatography, gas phase chromatography or quantitative NMR. The raw materials for pharmaceutical preparations with low impurities were screened out.

Benefits of technology

Through this method, the raw materials of pharmaceutical preparations with excellent stability and high quality can be effectively screened, and the stability and dissolution of pharmaceutical preparations can be improved, and the quality of the preparations can be ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114786727B_ABST
    Figure CN114786727B_ABST
Patent Text Reader

Abstract

The present invention provides a method for detecting minute mass differences of sodium dodecyl sulfate used as a raw material for manufacturing pharmaceutical preparations and discriminating sodium dodecyl sulfate of desired quality as a pharmaceutical preparation raw material. The present invention relates to a method for screening a preparation raw material for manufacturing a pharmaceutical preparation having excellent stability by pretreating the preparation raw material under specified accelerated conditions and detecting impurities. According to the method of the present invention, the quality of sodium dodecyl sulfate, a pharmaceutical preparation raw material that has no effect on the quality of a pharmaceutical preparation containing alectinib or a salt thereof, can be discriminated. A pharmaceutical composition manufactured using the SLS preparation raw material screened by the method of the present invention can provide a pharmaceutical preparation having excellent stability and good quality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for screening sodium lauryl sulfate as a raw material for pharmaceutical preparations in pharmaceutical preparations containing sodium lauryl sulfate, a method for evaluating the quality of pharmaceutical preparations containing the raw material for pharmaceutical preparations, and a method for producing a pharmaceutical preparation with high stability using the screened sodium lauryl sulfate. In addition, the present invention also relates to the screened raw material for pharmaceutical preparations, and a pharmaceutical composition or pharmaceutical preparation containing a certain amount of the screened raw material for pharmaceutical preparations and / or its impurities. Background Art

[0002] The compound represented by formula (I) (compound name: 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, generic name: alectinib) has an anaplastic lymphoma kinase (ALK: Anaplastic Lymphoma Kinase) inhibitory effect. Alectinib hydrochloride is used as a therapeutic drug for ALK fusion gene-positive unresectable progressive / recurrent non-small cell lung cancer (Non-Patent Document 1).

[0003] .

[0004] Since alectinib is a poorly soluble alkaline drug, its formulation has been reported as follows: preparing a composition in which a co-solvent is present (Patent Document 1); or preparing a capsule with good solubility by forming granules containing a compound represented by formula (I) or a salt thereof and allowing the granules to co-exist with a disintegrant (Patent Document 2).

[0005] Sodium lauryl sulfate is used as an additive for various pharmaceutical preparations represented by alectinib preparations (Non-Patent Document 1). It is known that preparations containing sodium lauryl sulfate lack stability, and deteriorated preparations containing sodium lauryl sulfate change in preparation characteristics. It is known that in order to stabilize preparations containing sodium lauryl sulfate, at least one selected from neutral salts and alkaline substances is blended (Patent Document 3).

[0006] However, until now, it has not been known that a slight difference in the mass of sodium lauryl sulfate used as a raw material for pharmaceutical preparations affects the deterioration of the preparations, nor is there a method for detecting the slight difference in the mass of sodium lauryl sulfate.

[0007] Prior art literature

[0008] Patent Literature

[0009] Patent document 1: Japanese Patent No. 4918630;

[0010] Patent document 2: Japanese Patent No. 5859712;

[0011] Patent document 3: Japanese Patent No. 4902928;

[0012] Non-patent literature

[0013] Non-patent literature 1: Alecensa 150mg capsule package insert, December 2018 revised edition. Summary of the invention

[0014] Problems to be solved by the invention

[0015] It is desirable to provide a method for detecting minute differences in the quality of sodium lauryl sulfate used as a raw material for manufacturing pharmaceutical preparations and for discriminating sodium lauryl sulfate of a desired quality as a raw material for pharmaceutical preparations.

[0016] Means for solving problems

[0017] In view of the above-mentioned problems, the present inventors have repeatedly conducted in-depth studies and found that slight mass differences in sodium dodecyl sulfate contained in preparations containing alectinib or a salt thereof can affect the stability or solubility of the preparations. They also found that the following method of pretreating sodium dodecyl sulfate under accelerated conditions can solve the above-mentioned problems, thereby completing the present invention.

[0018] That is, the present invention relates to the following method for screening a raw material for a pharmaceutical preparation containing sodium lauryl sulfate.

[0019] <1> The screening method is a method for screening pharmaceutical preparation raw materials containing sodium lauryl sulfate, characterized in that the impurities are detected after pre-treating the preparation raw materials under accelerated conditions.

[0020] <2> <1> The screening method is characterized in that the above-mentioned acceleration condition is a temperature condition of 65-75°C.

[0021] <3> <1> or <2> The screening method is characterized in that the above-mentioned accelerated condition is a humidity condition lower than 79%RH.

[0022] <4> <1> ~ <3> The screening method described in any one of the above is characterized in that the humidity condition of the acceleration bar is about 10% RH.

[0023] <5> <1> ~ <4> The screening method described in any one of the above is characterized in that the above-mentioned accelerated condition is a temperature condition of about 70° C. and a humidity condition of about 10% RH or less.

[0024] <6> <1> ~ <3> The screening method described in any one of the above, wherein the impurities are sulfate ions, dodecanol or sodium dodecyl sulfate / dodecanol complex.

[0025] <7> <1> ~ <6> The screening method described in any one of the above, wherein the impurities are detected by powder X-ray diffraction, ion exchange chromatography (chromatography), gas chromatography or quantitative NMR.

[0026] <8> <1> ~ <7> The screening method described in any one of the above, wherein the impurity is sulfate ion, and the impurity is detected by ion exchange chromatography.

[0027] <9> <1> ~ <8> The screening method described in any one of the above, wherein the pretreatment is performed under the accelerated conditions for more than 2 days.

[0028] <10> <1> ~ <8> The screening method described in any one of the above, wherein the pretreatment is performed under the above-mentioned accelerated conditions for 4 days.

[0029] <10a> <1> ~ <10> The screening method described in any one of the above, wherein the impurities are sulfate ions, and the pharmaceutical preparation raw materials having a sulfate ion content of 1 mg / L or less in the pharmaceutical preparation raw materials are screened.

[0030] <10b> <1> The screening method according to any one of <10a> to <10a>, wherein the impurity is sulfate ion, and the screening is performed for a pharmaceutical preparation raw material having a sulfate ion content of 1 mg / L or less in a solution obtained by dissolving about 100 mg of the pharmaceutical preparation raw material in 1 L of water.

[0031] Another embodiment of the present invention is a method for evaluating the quality of a pharmaceutical preparation, wherein the method omits the determination of impurities in a pharmaceutical preparation of alectinib, wherein the pharmaceutical preparation comprises sodium dodecyl sulfate, a pharmaceutical preparation raw material screened by detecting impurities under accelerated conditions.

[0032] <2> A quality evaluation method, which is a quality evaluation method for a pharmaceutical preparation containing a pharmaceutical preparation raw material comprising a compound represented by formula (I) or a salt thereof and sodium lauryl sulfate, comprising the following steps:

[0033] Step a: selecting a pharmaceutical preparation, wherein the pharmaceutical preparation uses a pharmaceutical preparation raw material screened by detecting impurities after pre-treating the pharmaceutical preparation raw material under accelerated conditions; and

[0034] Step b: omitting the determination of impurities in the pharmaceutical preparation selected in step a,

[0035] .

[0036] <2a> <2> The quality evaluation method is characterized in that the above-mentioned acceleration condition is a temperature condition of 65-75°C.

[0037] <2b> <2> Or the quality evaluation method described in <2a>, characterized in that the above-mentioned accelerated condition is a humidity condition lower than 79%RH.

[0038] <2c> <2> The quality evaluation method according to any one of <2b> to <2b>, wherein the acceleration condition is a humidity condition of about 10% RH.

[0039] <2d> <2> The quality evaluation method according to any one of <2c> to <2c>, wherein the acceleration condition is a temperature condition of about 70° C. and a humidity condition of about 10% RH or less.

[0040] <2e> <2> The quality evaluation method according to any one of <2d> to <2d>, wherein the impurity is sulfate ion, dodecanol or a sodium dodecyl sulfate / dodecanol complex.

[0041] <2f> <2> The quality evaluation method according to any one of <2e> to <2e>, wherein the impurities are detected by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR.

[0042] <2g> <2> The quality evaluation method according to any one of <2f> to <2f>, wherein the impurity is sulfate ion, and the impurity is detected by ion exchange chromatography.

[0043] <2h> <2> The quality evaluation method according to any one of <2g> to <2g>, wherein the pretreatment is performed under the accelerated conditions for 2 days or more.

[0044] <2i> <2> The quality evaluation method according to any one of <2h> to <2h>, wherein the pretreatment is performed under the accelerated conditions for 4 days.

[0045] <2j> <2> The quality evaluation method according to any one of <2i> to <2i>, wherein the impurity is sulfate ion, and the pharmaceutical preparation raw material having a sulfate ion content of 1 mg / L or less in the pharmaceutical preparation raw material is screened.

[0046] <2k> <2> The quality evaluation method described in any one of <2j> to <2j>, wherein the impurity is sulfate ion, and the pharmaceutical preparation raw material is screened for a sulfate ion content of 1 mg / L or less in a solution obtained by dissolving about 100 mg of the pharmaceutical preparation raw material in 1 L of water.

[0047] Furthermore, another embodiment of the present invention is a method for screening a raw material for a pharmaceutical preparation based on the storage conditions of sodium lauryl sulfate, which is a raw material for the preparation.

[0048] <11> A screening method, which is a screening method for a pharmaceutical preparation raw material containing sodium lauryl sulfate, comprising the following steps:

[0049] Step a, screening the batches (Lot) or packaging units of the above-mentioned preparation raw materials stored under specified conditions;

[0050] Step b, omitting the detection of impurities on the raw materials for pharmaceutical preparations screened in the above step a.

[0051] <12> <11> The screening method, wherein the above conditions are 30°C to 40°C and less than 47 days.

[0052] <13> <11> The screening method, wherein the above conditions are 30°C to 40°C and 47 days or less, and when the temperature exceeds 40°C, the cumulative time of exceeding 40°C and being below 60°C is within 48 hours.

[0053] <13a> <11> ~ <13> The screening method described in any one of the above, wherein the condition is 40°C.

[0054] <13b> <11> The screening method according to any one of <13a> to <13a>, wherein the above conditions are 45 days.

[0055] <14> <11> The screening method according to any one of <13b> to <13b>, wherein the above conditions are storage conditions during transportation.

[0056] In addition, another embodiment of the present invention also relates to a method for evaluating the quality of a pharmaceutical preparation by pretreating the pharmaceutical preparation under accelerated conditions.

[0057] <16> The method for evaluating the quality of a pharmaceutical preparation containing sodium lauryl sulfate is characterized by: detecting impurities after pre-treating the pharmaceutical preparation containing sodium lauryl sulfate under accelerated conditions.

[0058] <17> <16> The quality evaluation method, wherein the pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof,

[0059] .

[0060] <18> <16> ~ <17> The quality evaluation method described in any one of the above is characterized in that the above-mentioned acceleration condition is a temperature condition of 55 to 65°C.

[0061] <19> <16> ~ <18> The quality evaluation method described in any one of the above is characterized in that the above-mentioned accelerated condition is a temperature condition of about 60°C.

[0062] <20> <16> ~ <19> The quality evaluation method described in any one of the above, wherein the impurities are sulfate ions, dodecanol or a sodium dodecyl sulfate / dodecanol complex.

[0063] <21> <16> ~ <20> The quality evaluation method described in any one of the above, wherein the impurities are detected by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR.

[0064] <22> <16> ~ <21> The quality evaluation method described in any one of the above, wherein the impurity is dodecanol, and the impurity is detected by gas chromatography.

[0065] <23> <16> ~ <22> The quality evaluation method described in any one of the above, wherein the impurity is sulfate ion, and the impurity is detected by ion exchange chromatography.

[0066] <24> <16> ~ <23> The quality evaluation method described in any one of the above, wherein the pretreatment is performed under the accelerated conditions for more than 2 days.

[0067] <25> <16> ~ <24> The quality evaluation method described in any one of the above, wherein the pretreatment is carried out under the accelerated conditions for 7 days.

[0068] <26> <16> ~ <25> The quality evaluation method described in any one of the above, wherein the impurities are screened for pharmaceutical preparations in which the impurities are present in the form of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ions / sodium dodecyl sulfate (mol / mol%) at a level of 2% or less in the above preparation.

[0069] Furthermore, another embodiment of the present invention is a method for producing a pharmaceutical preparation of alectinib, comprising the following steps: pre-treating sodium dodecyl sulfate as a raw material for a pharmaceutical preparation under accelerated conditions and then screening.

[0070] <27> A manufacturing method, which is a manufacturing method for a pharmaceutical preparation containing sodium lauryl sulfate, comprising the following steps:

[0071] Step a, pretreating sodium lauryl sulfate as a raw material for a pharmaceutical preparation under accelerated conditions;

[0072] Step b, detecting impurities after the pretreatment in step a, and screening pharmaceutical preparation raw materials having a sulfate ion content of less than 1 mg / L as an impurity; and

[0073] Step c, using the pharmaceutical preparation raw materials screened in the above step b to manufacture a pharmaceutical preparation.

[0074] <28> <27> The manufacturing method, wherein the pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof,

[0075] .

[0076] <29> A manufacturing method, which is a method for manufacturing a pharmaceutical preparation containing a compound represented by formula (I) or a salt thereof and sodium lauryl sulfate, comprising the following steps:

[0077] Step a, using a pharmaceutical preparation raw material containing sodium lauryl sulfate to prepare the above-mentioned pharmaceutical preparation;

[0078] Step b, pretreating the pharmaceutical preparation prepared in step a above; and

[0079] Step c, after the pretreatment in step b, detecting impurities, screening for pharmaceutical preparations having a dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%) impurity ratio of less than 2%,

[0080] .

[0081] Moreover, another embodiment of the present invention is: a pharmaceutical preparation raw material or a pharmaceutical preparation thereof containing impurities in a specified ratio, a composition containing alectinib or a pharmaceutical preparation thereof, wherein the impurities are measured after pre-treating sodium dodecyl sulfate as a pharmaceutical preparation raw material under accelerated conditions.

[0082] <30> A composition, which is a pharmaceutical composition containing a compound represented by formula (I) or a salt thereof and sodium dodecyl sulfate, wherein, when a pharmaceutical preparation containing the composition is pretreated under accelerated conditions and then measured, the dodecanol / sodium dodecyl sulfate or sulfate ion / sodium dodecyl sulfate in the composition is contained in a ratio that has no effect on the dissolution of the preparation,

[0083] .

[0084] <31> <30> The composition, wherein the ratio of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%) in the composition is less than 2% as measured by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR.

[0085] <32> A preparation, which is a pharmaceutical preparation containing a compound represented by formula (I) or a salt thereof and sodium lauryl sulfate, wherein the ratio of dodecanol / sodium lauryl sulfate or sulfate ion / sodium lauryl sulfate in the preparation measured after pre-treating the preparation under accelerated conditions is contained in a ratio that does not affect dissolution,

[0086] .

[0087] <33> <32> The preparation, wherein the ratio of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%) in the preparation is less than 2% as measured by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR.

[0088] <34> A preparation, which is a pharmaceutical preparation containing sodium lauryl sulfate, wherein dodecanol / sodium lauryl sulfate or sulfate ion / sodium lauryl sulfate in the preparation measured after pre-treating the preparation under accelerated conditions is contained in a ratio that has no effect on the dissolution property of the pharmaceutical preparation.

[0089] <35> A pharmaceutical raw material, which is a pharmaceutical raw material containing sodium dodecyl sulfate, wherein the sulfate ion in the raw material measured by ion exchange chromatography after pretreatment of the pharmaceutical raw material under accelerated conditions is 1 mg / L or less.

[0090] The present invention also includes the following aspects.

[0091] (1) A screening method for a pharmaceutical preparation raw material containing sodium lauryl sulfate, characterized in that the preparation raw material is pretreated under accelerated conditions and then the impurities are detected.

[0092] (2) The screening method described in (1) is characterized in that the above-mentioned acceleration condition is a temperature condition of 65 to 75°C.

[0093] (3) The screening method described in (1) or (2) is characterized in that the above-mentioned accelerated condition is a humidity condition lower than 79%RH.

[0094] (4) The screening method according to any one of (1) to (3), wherein the acceleration condition is a humidity condition of about 10% RH.

[0095] (5) The screening method according to any one of (1) to (4), wherein the acceleration condition is a temperature condition of about 70° C. and a humidity condition of about 10% RH or less.

[0096] (6) The screening method according to any one of (1) to (3), wherein the impurity is sulfate ion, dodecanol, or a sodium dodecyl sulfate / dodecanol complex.

[0097] (7) The screening method according to any one of (1) to (6), wherein the impurities are detected by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR.

[0098] (8) The screening method according to any one of (1) to (7), wherein the impurity is sulfate ion and the impurity is detected by ion exchange chromatography.

[0099] (9) The screening method according to any one of (1) to (8), wherein the pretreatment is performed under the accelerated conditions for 2 days or more.

[0100] (10) The screening method according to any one of (1) to (8), wherein the pretreatment is performed under the accelerated conditions for 4 days.

[0101] (11) A method for evaluating the quality of a pharmaceutical preparation, characterized in that the pharmaceutical preparation is pretreated under accelerated conditions and then impurities are detected.

[0102] (11a) The quality evaluation method described in (11), wherein the above-mentioned pharmaceutical preparation contains sodium lauryl sulfate.

[0103] (12) The quality evaluation method described in (11) or (11a), wherein the acceleration condition is a temperature condition of about 60°C.

[0104] (13) The quality evaluation method according to (11), (11a) or (12), wherein the pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof,

[0105] .

[0106] (14) A method for producing a pharmaceutical preparation containing sodium lauryl sulfate, comprising the following steps:

[0107] Step a, pretreating sodium lauryl sulfate as a raw material for a pharmaceutical preparation under accelerated conditions;

[0108] Step b, detecting impurities after the pretreatment, and screening the preparation raw materials having a sulfate ion content of less than 1 mg / L as an impurity; and

[0109] Step c, using the above-mentioned preparation raw materials screened in the above-mentioned step b to manufacture a pharmaceutical preparation.

[0110] (15) The method of (14), wherein the pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof,

[0111] .

[0112] Effects of the Invention

[0113] According to the method of the present invention, the quality of sodium dodecyl sulfate (SLS) as a raw material for pharmaceutical preparations can be identified or screened, and a pharmaceutical composition manufactured using the SLS pharmaceutical preparation raw material screened by the method of the present invention can provide a pharmaceutical preparation with excellent stability and high quality.

[0114] According to the screening method of the present invention, by pre-treating the pharmaceutical preparation raw material sodium dodecyl sulfate under the prescribed accelerated conditions, a pharmaceutical preparation raw material can be screened, and the preparation raw material can be used to produce a pharmaceutical preparation with excellent stability. Alternatively, in the screening method of the present invention, the detection of impurities can be omitted according to the storage state of the pharmaceutical preparation raw material.

[0115] In addition, according to the quality evaluation method of the present invention, the quality of the pharmaceutical preparation can be evaluated by pre-treating sodium lauryl sulfate as a raw material for the pharmaceutical preparation under specified accelerated conditions and detecting the amount of impurities. Alternatively, according to the quality evaluation method of the present invention, whether the pharmaceutical preparation containing sodium lauryl sulfate is manufactured using sodium lauryl sulfate as a raw material for the pharmaceutical preparation that has been pre-treated under specified accelerated conditions and screened based on the amount of impurities can be evaluated to see whether the pharmaceutical preparation has a quality that allows the impurity measurement to be omitted.

[0116] Furthermore, according to the production method of the present invention, a pharmaceutical preparation containing sodium lauryl sulfate and having excellent stability can be produced by pretreating the pharmaceutical preparation raw material of sodium lauryl sulfate under prescribed accelerated conditions, screening the preparation raw material with low impurities, and using the screened pharmaceutical preparation raw material to produce the pharmaceutical preparation.

[0117] In addition, the present invention can provide a pharmaceutical preparation raw material that can be used to produce a pharmaceutical preparation having excellent stability, or an alectinib-containing composition or pharmaceutical preparation that contains impurities that have no effect on solubility and are in a predetermined ratio or less. BRIEF DESCRIPTION OF THE DRAWINGS

[0118] [ Figure 1A ] is a graph showing the measurement results of powder X-ray diffraction when Lot 1 of sodium dodecyl sulfate was stored under temperature condition 1A.

[0119] [ Figure 1B ] is a graph showing the measurement results of powder X-ray diffraction when Lot 2 of sodium dodecyl sulfate was stored under temperature condition 1A.

[0120] [ Figure 1C ] is a graph showing the measurement results of powder X-ray diffraction when Lot 1 of sodium dodecyl sulfate was stored under temperature condition 1B.

[0121] [ Figure 1D ] is a graph showing the measurement results of powder X-ray diffraction when Lot 2 of sodium dodecyl sulfate was stored under temperature condition 1B.

[0122] [ Figure 2A ] is a graph showing the measurement results of powder X-ray diffraction when Lot 1 of sodium dodecyl sulfate was stored under humidity condition 2A.

[0123] [ Figure 2B ] is a graph showing the measurement results of powder X-ray diffraction when Lot 2 of sodium dodecyl sulfate was stored under humidity condition 2A.

[0124] [ Figure 2C ] is a graph showing the measurement results of powder X-ray diffraction when Lot 1 of sodium dodecyl sulfate was stored under humidity condition 2B.

[0125] [ Figure 2D ] is a graph showing the measurement results of powder X-ray diffraction when Lot 2 of sodium dodecyl sulfate was stored under humidity condition 2B.

[0126] [ Figure 3 ] is a graph showing the measurement results of powder X-ray diffraction of a sodium dodecyl sulfate / dodecanol complex.

[0127] [ Figure 4 ] is a scanning electron micrograph of sodium dodecyl sulfate and sodium dodecyl sulfate / dodecanol complex.

[0128] [ Figure 5 ] is a graph of the proton nuclear magnetic resonance spectra of sodium dodecyl sulfate and sodium dodecyl sulfate / dodecanol complex.

[0129] [ Fig. 6A ] is a graph showing the measurement results of powder X-ray diffraction when Lot 1 of sodium dodecyl sulfate was stored at a temperature of 70°C and a relative humidity of about 10% (LiCl saturated aqueous solution).

[0130] [ Figure 6B ] is a graph showing the measurement results of powder X-ray diffraction when Lot 2 of sodium dodecyl sulfate was stored at a temperature of 70°C and a relative humidity of about 10% (LiCl saturated saline solution).

[0131] [ Fig. 7A ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot A was stored under temperature condition 5A.

[0132] [ Figure 7B ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot B was stored under temperature condition 5A.

[0133] [ Figure 7C ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot A was stored under temperature condition 5B.

[0134] [ Fig.7D ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot B was stored under temperature condition 5B.

[0135] [ Fig. 7E ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot A was stored at a temperature condition of 5°C.

[0136] [ Figure 7F ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot B was stored at a temperature condition of 5°C.

[0137] [ Fig. 8A ] is the dissolution test curve when the preparation Lot C is stored at a temperature of 60°C.

[0138] [ Figure 8B ] is the dissolution test curve when preparation Lot D was stored at a temperature of 60°C.

[0139] [ Fig.9A ] is a graph showing the measurement results of powder X-ray diffraction when the preparation Lot C was stored at a temperature of 60°C.

[0140] [ Fig. 9B ] is a graph showing the measurement results of powder X-ray diffraction when preparation Lot D was stored at a temperature of 60°C.

[0141] [ Fig. 10A ] is the dissolution test curve when preparation Lot E was stored at a temperature of 60°C.

[0142] [ Fig. 10B ] is the dissolution test curve when preparation Lot F was stored at a temperature of 60°C.

[0143] [ Fig. 10C ] is the dissolution test curve when the preparation Lot G was stored at a temperature of 60°C.

[0144] [ Fig. 10D ] is the dissolution test curve when the preparation Lot H was stored at a temperature of 60°C.

[0145] [ Fig.10E ] is the dissolution test curve when preparation Lot I was stored at a temperature of 60°C.

[0146] [ Fig.10F ] is the dissolution test curve when preparation Lot J was stored at a temperature of 60°C.

[0147] [ Figure 10G ] is the dissolution test curve when the preparation Lot K was stored at a temperature of 60°C.

[0148] [ Fig.11 ] is a graph showing the measurement results of dodecanol by GC / MS when preparations Lot A and Lot B were stored at a temperature of 60°C. DETAILED DESCRIPTION

[0149] Hereinafter, the present invention will be described.

[0150] In the present invention, "sodium lauryl sulfate" is a known substance as an additive for pharmaceutical preparations, and is particularly a substance constituting the pharmaceutical composition of the pharmaceutical preparation as a cosolvent for the poorly soluble drug, i.e., alectinib. It is known that sodium lauryl sulfate exists as a hydrate, a 1 / 2 hydrate, a 1 / 8 hydrate, and a non-solvate (document name: Journal of Crystal Growth 263 (2004) 480-490), which is usually stored at room temperature and preferably used within 1 year from the time of manufacture. All forms can be used as raw materials for the pharmaceutical preparations of the present invention.

[0151] "Raw materials for pharmaceutical preparations" refer to substantially pure single compounds (e.g., sodium dodecyl sulfate, etc.) used as additives for pharmaceutical preparations, including active ingredients such as alectinib. Raw materials for pharmaceutical preparations refer to raw materials used for the industrial manufacture of the pharmaceutical preparations, which contain the desired compound in an amount of kilograms or more. "Substantially pure" means that a certain degree of impurities is allowed, but the desired compound is usually contained in a circulating degree. In the present invention, raw materials for pharmaceutical preparations can be purchased from manufacturers as commercially available raw materials, or can be raw materials manufactured by oneself or by other companies on behalf of others. In addition, raw materials for pharmaceutical preparations can use raw materials that have just been purchased or manufactured, or raw materials that have been purchased / manufactured for a specified period of time, such as more than 1 year, can be used.

[0152] It should be noted that the "pharmaceutical preparation raw material containing sodium lauryl sulfate" refers to a pharmaceutical preparation raw material containing substantially pure sodium lauryl sulfate, and a trace amount of sulfate ions, dodecanol, or a sodium lauryl sulfate / dodecanol complex may be present as impurities.

[0153] "Screening" refers to selecting a higher purity pharmaceutical preparation raw material or pharmaceutical preparation, specifically, refers to selecting a batch or packaging unit of a preparation raw material or pharmaceutical preparation with fewer impurities by measuring the impurity content in a batch or packaging unit of each preparation raw material or pharmaceutical preparation. Screening pharmaceutical preparation raw materials refers to preferably selecting a higher purity pharmaceutical preparation raw material, and more preferably selecting a batch or packaging unit of a preparation raw material whose impurity content is suitable for the purity test recorded in the Japanese Pharmacopoeia (17th revised edition). It should be noted that a batch refers to the minimum unit of production / delivery of a raw material or product manufactured within a prescribed period under the same conditions. A packaging unit refers to a unit in which more than one batch of pharmaceutical preparation raw materials or pharmaceutical preparations are packaged in a prescribed weight or quantity unit. The screening of pharmaceutical preparation raw materials is more preferably the following method: when the pharmaceutical preparation raw material is sodium dodecyl sulfate and the impurity is sulfate ion, when the sample is dissolved in water and the content of sulfate ions is selected, the batch or packaging unit is preferably 5 mg / L or less, preferably 3 mg / L or less, and most preferably 1 mg / L or less. Alternatively, the method comprises selecting a batch or packaging unit in which the content of sulfate ions in a solution of about 100 mg / L obtained by dissolving the sample in water is 1 mg / L or less. In the case of screening pharmaceutical preparations, "screening" refers to a method in which, when the impurities of the pharmaceutical preparation are dodecanol, sulfate ions, or sodium dodecyl sulfate / dodecanol complexes, when measured by powder X-ray diffraction, ion exchange chromatography, gas chromatography, or quantitative NMR, the batch or packaging unit is selected in which the content of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ions / sodium dodecyl sulfate (mol / mol%) is 5% or less, preferably 3% or less, and most preferably 2% or less.

[0154] Ion chromatography is a type of liquid chromatography that mainly measures ion species. With an eluent as the mobile phase, it can separate and quantify ion species in a sample solution in a packed column with an ion exchanger as the stationary phase. Gas chromatography can separate through the interaction between the stationary phase and the substance, and can perform qualitative analysis based on the time it takes to reach the detector and quantitative analysis based on the signal from the detector. Measurements based on powder X-ray diffraction can be performed, for example, according to conventional methods such as the "Powder X-ray Diffraction Measurement Method" described in the Japanese Pharmacopoeia (17th Revised Edition).

[0155] Quantitative NMR is a method for quantitative analysis based on the principle that the area of ​​the single peak observed on the NMR spectrum is proportional to the number of hydrogen atoms contained in the sample and is independent of the chemical structure of the substance. Therefore, by using a substance with a known purity other than the analysis object component as a standard substance, the absolute quantification of the analysis object component can be performed. Preferably, gas chromatography or ion chromatography using an anion exchange column, the preferred mobile phase, column, and detector of the ion chromatography are as follows.

[0156] Mobile phase (eluent): 5 mM Na2CO3 solution or 20 mM NaOH solution;

[0157] Column: When using a 5 mM Na2CO3 solution, Metrosep A Supp 7-250 / 4.0 (manufactured by Metrohm) can be used, or when using a 20 mM NaOH solution, Ion Pac AS11-HC (diameter 4 mm, length 250 mm) (manufactured by Thermo Scientific) can be used;

[0158] Detector: Conductivity meter.

[0159] Preferred gas chromatography columns and measurement conditions are as follows.

[0160] Column: HP-5MS UI, 0.25mm ID × 30m, 0.25 μ m (manufactured by Agilent);

[0161] Injection volume: 1.0 μ L;

[0162] Split ratio: 1:10;

[0163] Column temperature: 40°C (1 minute) → (20°C / minute) → 180°C → (5°C / minute) → 190°C → (50°C / minute) → 300°C (4 minutes);

[0164] Injector temperature: 300℃;

[0165] Interface temperature: 30℃;

[0166] Carrier gas: He;

[0167] Flow rate: 1 mL / min;

[0168] Ion voltage: 70 eV;

[0169] Ionization mode: ESI-;

[0170] Measurement mode: SIM;

[0171] Monitored ions (m / z): 83.0.

[0172] "Accelerated conditions" refer to conditions that are more severe than the usual storage state, and specifically, temperature or humidity are conditions that are more severe than the usual storage state. Specifically, the accelerated conditions for the temperature of the pharmaceutical preparation raw material refer to a temperature condition of 50°C or more, preferably about 60°C or more, more preferably about 60°C to 80°C, further preferably about 65°C to 75°C, and most preferably about 70°C. The humidity condition used under the accelerated condition is a humidity condition of 80%RH or less, preferably less than 79%RH, or more preferably less than about 10%RH.

[0173] In addition, if the pharmaceutical preparation raw material is stored under certain conditions, the proportion of impurities generated can be suppressed to a low level. Therefore, if a pharmaceutical preparation containing the pharmaceutical preparation raw material after storing the pharmaceutical preparation raw material under the conditions is selected, the measurement of impurities can be omitted.

[0174] The accelerated conditions regarding the temperature of the pharmaceutical preparation refer to temperature conditions of 50°C or higher, preferably about 50°C to 70°C or higher, more preferably about 55°C to 65°C, and most preferably about 60°C.

[0175] It should be noted that "storage" means that the pharmaceutical preparation raw materials are stored (preserved) for a certain period of time in a warehouse, storage room, cargo, etc. where the temperature and humidity can be controlled from the time of production to the time of use, and also includes transportation that requires more than one day.

[0176] In the present invention, "prescribed conditions" refer to the temperature or the number of days during the storage period. Specifically, the temperature and the number of days are preferably 40°C or less and 47 days or less, more preferably 30°C to 40°C and 47 days or less, and most preferably 30°C to 40°C and 45 days or less.

[0177] In the case of temperature conditions, "exceeding the prescribed conditions" means that the storage is carried out at a temperature higher than 40°C. However, even in the case of exceeding the temperature condition, as long as it is within the prescribed range, the influence on the generation of impurities is small, so the measurement of impurities can be omitted. Specifically, in the case of exceeding 40°C, if the cumulative time of exceeding 40°C and being below 60°C is within 48 hours, the measurement of impurities can be omitted.

[0178] In the case of the conditions regarding the number of days, "exceeding the prescribed conditions" means storage at a temperature of 40°C or less for 47 days, preferably storage for more than 45 days. However, the measurement of impurities can also be omitted when the storage temperature is room temperature to 30°C and the storage period is less than 1 year.

[0179] In this way, even when the storage is performed under conditions exceeding the conditions (additional conditions) under which the measurement of impurities can be omitted, it still meets the "exceeding the prescribed conditions".

[0180] It should be noted that, in the present specification, “about” is used in the sense of allowing ±10%.

[0181] "Pretreatment" refers to a prescribed treatment applied to a raw material for a pharmaceutical preparation before it is used to manufacture a pharmaceutical preparation. Specifically, the prescribed treatment refers to leaving the raw material for a pharmaceutical preparation to stand for a prescribed period under the above-mentioned accelerated conditions. For raw materials for pharmaceutical preparations, the prescribed period refers to more than 1 day, preferably more than 2 days, more preferably more than 3 days, and even more preferably 4 days. For pharmaceutical preparations, the prescribed period refers to more than 5 days, preferably more than 7 days, even more preferably more than 7 days and within 14 days, and most preferably within 7 days.

[0182] "Impurities" refer to substances other than the raw materials contained in each batch or each packaging unit of the raw materials for pharmaceutical preparations, such as raw materials used to manufacture raw materials for pharmaceutical preparations, their decomposition products, complexes, etc. Alternatively, it refers to the manufacturing raw materials, decomposition products, complexes, etc. of the raw materials for pharmaceutical preparations contained in the pharmaceutical preparations. For example, in the case where the raw material for pharmaceutical preparations is sodium dodecyl sulfate, or in the case of a pharmaceutical preparation containing sodium dodecyl sulfate, the main impurities are sulfate ions, dodecanol, or sodium dodecyl sulfate / dodecanol complexes. Sulfate ions as impurities in the raw materials for pharmaceutical preparations can be measured by ion exchange chromatography. In the solution obtained by dissolving the sample in water, the acceptable concentration of sulfate ions is 5 mg / L or less, preferably 3 mg / L or less, and most preferably 1 mg / L or less. Dodecanol as an impurity in pharmaceutical preparations can be measured by powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR in the same manner as used in "Screening", and its concentration is preferably 2% or less in terms of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%).

[0183] "The ratio that has no effect on dissolution" refers to the ratio of impurities when the dissolution of a pharmaceutical preparation containing a specified amount of impurities is compared with the dissolution of a pharmaceutical preparation containing no impurities, and the difference is within 10%. For example, for pharmaceutical preparations containing various contents of impurities, in a dissolution test at 100 rpm and 37°C using 900 mL of the 16th revised edition of the Japanese Pharmacopoeia dissolution test solution No. 1 containing 7% polyoxyethylene (10) octylphenyl ether, based on the 16th revised edition of the Japanese Pharmacopoeia dissolution test paddle method, the drug dissolution rate at a specified time point, preferably at a time point of 75 minutes, is compared with the drug dissolution rate of the pharmaceutical preparation containing no impurities, and the ratio is calculated from the amount of impurities in the preparation whose difference is within 10%. Specifically, the impurities of the pharmaceutical preparation containing sodium dodecyl sulfate are preferably less than 2% in terms of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ions / sodium dodecyl sulfate (mol / mol%).

[0184] "Detection" refers to qualitatively or quantitatively confirming substances (impurities) other than raw materials contained in each batch or packaging unit of a pharmaceutical preparation or a raw material for a pharmaceutical preparation. For example, when the raw material for a pharmaceutical preparation is sodium dodecyl sulfate, or a pharmaceutical preparation containing sodium dodecyl sulfate, the presence or absence of sulfate ions, dodecanol, or a sodium dodecyl sulfate / dodecanol complex as impurities is qualitatively or quantitatively confirmed by using powder X-ray diffraction, ion exchange chromatography, gas chromatography, or quantitative NMR, as in the method used in "screening".

[0185] "Pharmaceutical preparation" refers to a pharmaceutical composition that contains a physiologically active substance as an effective ingredient and also contains a pharmaceutically acceptable additive in a form suitable for oral administration. In the present invention, oral preparations are preferred. "Oral preparations" refer to preparations that can be administered orally, and the active ingredient is mainly absorbed from the intestine. Oral preparations include solid preparations and liquid preparations. Solid preparations are preferred in the present invention. Specifically, they include: tablets, capsules, powders, lozenges, chewable tablets and other solid preparations, among which tablets are preferred. In the pharmaceutical preparation of the present invention, excipients, lubricants, coating agents, binders, disintegrants, stabilizers, flavoring agents, diluents and the like commonly used in pharmaceutical preparations may be included as additives. As the pharmaceutical preparation in the present invention, preferably a pharmaceutical preparation containing a compound represented by formula (I) or a salt thereof, more preferably a pharmaceutical preparation containing alectinib hydrochloride,

[0186] .

[0187] In the present invention, the pharmaceutical preparation used for quality evaluation may be a self-made pharmaceutical preparation or a commercially available pharmaceutical preparation.

[0188] "Pharmaceutical composition" refers to a mixture of two or more substances used for the treatment / prevention of a disease, etc., containing a physiologically active substance as an active ingredient and a pharmaceutically acceptable additive. The physiologically active substance in the present invention is preferably a compound represented by formula (I) or a salt thereof,

[0189] .

[0190] As additives, sodium lauryl sulfate is preferably contained, and lactose hydrate, hydroxypropylcellulose, carmellose calcium, and magnesium stearate may also be contained.

[0191] "Quality evaluation method" refers to a method for evaluating the quality of the pharmaceutical preparation by qualitatively or quantitatively measuring the impurities in the above-mentioned pharmaceutical preparation. The qualitative or quantitative determination of impurities can be carried out by using powder X-ray diffraction, ion exchange chromatography, gas chromatography or quantitative NMR, etc. A preferred quality evaluation method is to evaluate the quality of the pharmaceutical preparation using the content of impurities in the pharmaceutical preparation. Specifically, using the method adopted in "screening", a pharmaceutical preparation having an impurity content of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%) of 5% or less, preferably 3% or less, and more preferably 2% or less as a pharmaceutical preparation is evaluated as a pharmaceutical preparation of preferred quality.

[0192] The compound represented by the formula (I) refers to the compound represented by the formula (I), namely, 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, commonly known as Alectinib.

[0193] .

[0194] The "salt" of the compound represented by formula (I) is preferably a pharmaceutically acceptable salt. Examples of the "pharmaceutically acceptable salt" include: sulfonates such as hydrochlorides, hydrobromides, hydroiodides, phosphates, phosphonates, sulfates, methanesulfonates, and p-toluenesulfonates; carboxylates such as acetates, citrates, malates, tartrates, succinates, and salicylates; alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; ammonium salts (NH4X: X is a monovalent acid radical), alkylammonium salts, dialkylammonium salts, trialkylammonium salts, tetraalkylammonium salts, and the like.

[0195] The hydrochloride is preferred, and the monohydrochloride is most preferred.

[0196] The compound represented by formula (I) or a salt thereof can be produced by a known method (for example, the method described in Patent Document 2).

[0197] The monohydrochloride of the compound represented by formula (I) may be amorphous or crystalline. In the case of crystals, it is preferred that the diffraction angles (2 θ ) has a peak (I-type crystal). In addition, the monohydrochloride of the compound represented by formula (I) may be a hydrate. The amorphous monohydrochloride of the compound represented by formula (I) can be manufactured by the method described in WO2016 / 021707, and the crystal having the peak can be manufactured by the method described in WO2015 / 163447.

[0198] The compound represented by formula (I) or a salt thereof is contained in an amount of 20 to 70% by weight, preferably 35 to 60% by weight, more preferably 45 to 50% by weight, based on the total weight of the composition, in terms of free form.

[0199] The preparation obtained by the production method of the present invention contains 150 mg to 800 mg, preferably 150 mg to 400 mg, particularly preferably 150 mg to 300 mg of the compound represented by formula (I) or a salt thereof per unit preparation in terms of free form. Specifically, the preparation is a 150 mg capsule preparation, or a 150 mg, 300 mg, or 600 mg tablet. Example

[0200] Example 1: Pretreatment Condition Setting (Temperature) of Evaluation Method of Sodium Lauryl Sulfate

[0201] Sodium lauryl sulfate obtained from the same manufacturer in different batches (Lot 1 (manufacturing date: 2015.12.22) and Lot 2 (manufacturing date: 2017.3.10)) was appropriately placed in glass vials and stored in a closed system under condition 1A: temperature 60°C and condition 1B: temperature 70°C. Powder X-ray diffraction (XRPD) measurements were performed on the samples before storage, after 3 days, and after 4 days of storage under the conditions shown below.

[0202] Powder X-ray diffraction determination method:

[0203] Measurement device: X'Pert-Pro MPD (manufactured by PANalytical);

[0204] For cathode: Cu;

[0205] Tube voltage: 45kV;

[0206] Tube current: 40mA;

[0207] Step width: 0.02;

[0208] Scan axis: 2 θ ;

[0209] Sampling time per step: 43 seconds;

[0210] Scanning range: 3-40˚.

[0211] The powder X-ray diffraction patterns of Lot 1 and Lot 2 when stored under Condition 1A and Condition 1B are shown in Figure 1. In Lot 2, the XRPD patterns did not change even after 4 days of storage under Condition 1A and Condition 1B.

[0212] On the other hand, in Lot 1, after 4 days of storage under condition 1A and 3 days of storage under condition 1B, the diffraction angles (2 θ )New peaks were observed.

[0213] The time points at which new peaks were first detected in the XRPD of Lot 1 and Lot 2 under Condition 1A and Condition 1B are shown below.

[0214] Condition 1A

[0215] Lot 1: After 4 days of storage;

[0216] Lot 2: No new peaks were detected after 4 days of storage;

[0217] Condition 1B

[0218] Lot 1: After 3 days of storage;

[0219] Lot 2: No new peaks were detected after 4 days of storage.

[0220] Therefore, it was determined that the condition 1B with a high temperature was a condition that allowed the evaluation of Lot 1 and Lot 2 of sodium lauryl sulfate to be performed earlier, and the humidity of Example 2 was further investigated.

[0221] Example 2: Pretreatment Condition Setting (Humidity) for Evaluation Method of Sodium Lauryl Sulfate

[0222] About 250 mg of different lots (Lot 1 and Lot 2) of sodium dodecyl sulfate used in Example 1 were placed in glass vials and stored in an open system under Condition 2A: temperature 70°C, relative humidity about 79% (NaCl saturated saline solution) and Condition 2B: temperature 70°C, relative humidity about 10% (LiCl saturated saline solution). *1 The samples before storage under condition 2B, and after storage for 1 day, 2 days, 3 days, and 6 days were subjected to powder X-ray diffraction measurement according to the conditions shown in Example 1.

[0223] *1: Since Lot 1 became liquid after being stored for 2 and 3 days under Condition 2A, powder X-ray diffraction measurement was not performed.

[0224] The powder X-ray diffraction patterns of Lot 1 and Lot 2 when stored under Condition 2A and Condition 2B are shown in Figure 2. Under Condition 2B, the XRPD pattern of Lot 2 did not change until 6 days after storage. On the other hand, in Lot 1, the diffraction angles (2 θOn the other hand, under condition 2A, a new peak was observed in Lot 1 after 1 day of storage, and a peak was observed in Lot 2 after 3 days.

[0225] Shown are the time points at which new peaks were first detected in the XRPD of Lot 1 and Lot 2 under Condition 2A and Condition 2B.

[0226] Condition 2A

[0227] Lot 1: After 1 day of storage;

[0228] Lot 2: After 3 days of storage;

[0229] Condition 2B

[0230] Lot 1: After 3 days of storage;

[0231] Lot 2: No new peaks were detected after 6 days of storage.

[0232] Based on the above results, it can be judged that the condition 2B with low relative humidity is a condition that is more capable of identifying sodium dodecyl sulfate Lot 1 and Lot 2, and is used to screen sodium dodecyl sulfate samples.

[0233] Example 3: Identification of impurities in sodium lauryl sulfate during storage

[0234] About 85 mg of sodium dodecyl sulfate was added to about 2 mL of dodecanol, and the mixture was stirred for about 12 hours while being maintained at 30°C. The precipitated solid was filtered out to obtain white crystals. The above crystals (sodium dodecyl sulfate / dodecanol complex) were subjected to powder X-ray diffraction analysis under the conditions of Example 1. The results are shown in FIG. Figure 3 The diffraction angles near 4.9° and 7.4° observed in the sodium dodecyl sulfate / dodecanol complex (2 θ ) is very consistent with the peak of the unknown substance observed when sodium dodecyl sulfate was stored in Example 1 and Example 2.

[0235] In addition, sodium dodecyl sulfate and sodium dodecyl sulfate / dodecanol complex were observed using a scanning electron microscope under the following conditions. The results are shown in Figure 4 Sodium lauryl sulfate is a thin plate-like crystal, whereas the sodium lauryl sulfate / dodecanol complex has a different shape.

[0236] Scanning electron microscope measurement conditions:

[0237] Ion sputtering device: JFC-1500 (manufactured by JEOL);

[0238] Measurement device: SEM VE-9800 (manufactured by Keyence);

[0239] Accelerating voltage: 2 kV;

[0240] Objective lens magnification: 100x.

[0241] In order to confirm the molar ratio of sodium dodecyl sulfate to dodecanol in the sodium dodecyl sulfate / dodecanol complex, about 6 mg of the sodium dodecyl sulfate / dodecanol complex was dissolved in 1 mL of 99.8% methanol-d4, and the proton nuclear magnetic resonance spectrum (1H-NMR spectrum) was measured under the conditions shown below.

[0242] Measurement device: ECP500 (manufactured by JEOL);

[0243] Solvent: methanol-d4;

[0244] X resolution: 0.22673 [Hz];

[0245] Scan times: 16;

[0246] Relaxation delay: 60 seconds.

[0247] Proton NMR spectra are shown in Figure 5 The quantitative results are as follows: the molar ratio of sodium dodecyl sulfate to dodecyl alcohol in the sodium dodecyl sulfate / dodecanol complex is 1.18:1.00.

[0248] The above results revealed that sodium lauryl sulfate decomposed during storage and formed a complex with dodecanol, which is one of the decomposition products.

[0249] Example 4: Study of Storage Period under Accelerated Conditions (XRPD, Ion Chromatography)

[0250] About 250 mg of sodium dodecyl sulfate was placed in a glass vial and stored in an open system at a temperature of 70° C. and a relative humidity of about 10% (LiCl saturated saline solution). Powder X-ray diffraction measurement was performed on the samples before storage and after storage for 1 day, 2 days, 3 days, 4 days, 7 days, and 11 days according to the conditions shown in Example 1.

[0251] The XRPD patterns of different batches of sodium dodecyl sulfate (Lot 1, Lot 2) used in Example 1 until 11 days of storage are shown in Figure 6. In Lot 2, no peaks of the sodium dodecyl sulfate / dodecanol complex were detected until 11 days of storage, while in Lot 1, peaks representing the sodium dodecyl sulfate / dodecanol complex were detected in the sample after 3 days of storage.

[0252] In addition, regarding Lot 1 and Lot 2 after storage for 4 days, sulfate ions generated by decomposition of sodium dodecyl sulfate were quantified by the ion chromatography method shown below.

[0253] As a result, the sulfate ion concentration in the sample solution prepared using sodium dodecyl sulfate Lot 2 was less than 1 mg / L, whereas the sulfate ion concentration in the sample solution prepared using sodium dodecyl sulfate Lot 1 was 24.1 mg / L, indicating that sodium dodecyl sulfate Lot 1 was decomposing after being stored for 4 days.

[0254] Determination of sulfate ions based on ion chromatography:

[0255] About 5 mg of sodium dodecyl sulfate was weighed and water was added to 50 mL. Ultrasonic irradiation was performed for 15 minutes and the membrane filter (DISMIC-25HP PTFE 0.45 μ m HYDROPHILIC, ADVANTEC) was filtered. The filtrate was passed through a washed solid phase extraction column (Dionex OnGuard II RP, ThermoFisher Scientific), and the eluent was used as the sample solution. In addition, sulfate ion standard solution for ion chromatography (1 g / L, Wako Pure Chemical Industries) was used to prepare solutions with sulfate ion concentrations of 1 mg / L, 2 mg / L, 3 mg / L, 4 mg / L, and 5 mg / L as standard solutions. Compact IC Flex (Metrohm) was used for ion chromatography, and the test was carried out according to the following analysis conditions.

[0256] Column: Metrosep A Supp 7-250 / 4.0 (manufactured by Metrohm);

[0257] Guard column: Metrosep A Supp 4 / 5 S-Guard / 4.0 (manufactured by Metrohm);

[0258] Suppressor: MSM, MCS (manufactured by Metrohm);

[0259] Eluent: 5 mM Na2CO3 solution;

[0260] Washing liquid: pure water;

[0261] Flow rate: 0.8 mL / min;

[0262] Sample temperature: 20°C;

[0263] Column temperature: 45°C;

[0264] Injection volume: 10ml;

[0265] Measurement time: 24 minutes.

[0266] The sulfate ion concentration in the sample solution was calculated based on a calibration curve prepared using the standard solution.

[0267] Example 5: Discussion of pretreatment methods for quality evaluation of pharmaceutical preparations (temperature)

[0268] As shown in Example 3, sodium lauryl sulfate contains impurities depending on the batch. Therefore, according to Example 1 of Japanese Patent 5859712, the Alecensa capsule (150 mg) preparation of preparation Lot A was prepared using sodium lauryl sulfate Lot 1, and the Alecensa capsule (150 mg) preparation of preparation Lot B was prepared using sodium lauryl sulfate Lot 3 (manufacturing date: 2015.10.02) produced by the same manufacturer but with a different manufacturing date, and the presence of the complex as an impurity was investigated under different storage conditions.

[0269] Preparations Lot A and Lot B were placed in glass vials and stored in a closed system at temperature conditions 5A: 60° C., condition 5B: 70° C., and condition 5C: 80° C. Powder X-ray diffraction measurement was performed under the conditions shown in Example 1 for samples stored for 4 days, 7 days, 10 days, and 14 days under condition 5A, 2 days and 3 days under condition 5B, and 1 day under condition 5C.

[0270] The powder X-ray diffraction patterns of Lot A and Lot B when stored under conditions 5A, 5B, and 5C are shown in Figure 7. Under condition 5A, the peak of the sodium dodecyl sulfate / dodecanol complex was not detected in the sample stored for 10 days in Lot B, whereas the peak was detected in the sample stored for 7 days in Lot A.

[0271] The graph shows the time point at which the peak of the sodium dodecyl sulfate / dodecanol complex was first detected in the XRPD patterns of Lot A and Lot B under each temperature condition.

[0272] Condition 5A

[0273] Lot A: After 7 days of storage;

[0274] Lot B: After 14 days of storage;

[0275] Condition 5B

[0276] Lot A: After 2 days of storage

[0277] Lot B: After 2 days of storage;

[0278] Condition 5C

[0279] Lot A: After 1 day of storage;

[0280] Lot B: After 1 day of storage.

[0281] Therefore, it was determined that condition 5A, 60°C, was a condition that could evaluate the stability of preparations Lot A and Lot B, and was used for quality evaluation of preparations.

[0282] Example 6: Effect of impurities in sodium lauryl sulfate on formulations

[0283] In order to investigate the effect of impurities in sodium lauryl sulfate on the preparation, the sodium lauryl sulfate Lot 1 used in Example 1 was used to manufacture the Alecensa capsule (150 mg) preparation of preparation Lot C in the same manner as in Example 5, and the sodium lauryl sulfate Lot 4 (manufacturing date: 2016.06.28) with a different manufacturing date from the same manufacturer was used to manufacture the Alecensa capsule (150 mg) preparation of preparation Lot D, and the dissolution rates of each were investigated.

[0284] Preparations Lot C and Lot D were placed in glass vials and stored in a closed system at 60°C. Dissolution tests were performed on the samples before and after 7 days of storage under the following conditions. The results were as follows: the dissolution curve of Lot D was the same as before storage, while the dissolution rate of Lot C was significantly lower than before storage (Figure 8).

[0285] Dissolution test implementation method:

[0286] As the test solution, 900 mL of Japanese Pharmacopoeia Dissolution Test Solution 1 containing 7% polyoxyethylene (10) octylphenyl ether was used, and the test was conducted at 37° C. and 100 rpm according to the Japanese Pharmacopoeia Dissolution Test Paddle Method.

[0287] In addition, the samples before storage and after storage for 5, 6, 7, 8, 9, 12, and 14 days were subjected to powder X-ray diffraction measurement under the conditions shown in Example 1. As a result, in Lot D, the peak of the sodium dodecyl sulfate / dodecanol complex was not detected until after storage for 14 days, whereas in Lot C, the peak was detected after storage for 7 days ( FIG. 9 ).

[0288] The samples after storage for 7 days were further subjected to quantification of dodecanol by GC / MS according to the method shown below.

[0289] Determination of dodecanol based on GC / MS:

[0290] Take out the capsule contents of 3 capsules of each preparation and mix them. Measure 50mg capsule contents and add hexane to 25mL. Carry out 30 minutes of ultrasonic irradiation, transfer the solution to a centrifuge tube and centrifuge, and use the supernatant as a sample solution. Use 1-dodecanol (Wako Pure Chemical Industries, Ltd.) to modulate the solution of 1g / L, 5g / L, 10g / L, 50g / L, 100g / L of dodecanol concentration as a standard solution. GC / MS uses 7850A (Agilent manufactures) and is tested according to the following analysis conditions.

[0291] Column: HP-5MS UI, 0.25mm ID × 30m, 0.25 μ m (manufactured by Agilent);

[0292] Injection volume: 1.0µL;

[0293] Split ratio: 1:10;

[0294] Column temperature: 40°C (1 minute) -> (20°C / minute) -> 180°C -> (5°C / minute) -> 190°C -> (50°C / minute) -> 300°C (4 minutes);

[0295] Injector temperature: 300℃;

[0296] Interface temperature: 30℃;

[0297] Carrier gas: He;

[0298] Flow rate: 1 mL / min;

[0299] Ion voltage: 70 eV;

[0300] Ionization mode: ESI-;

[0301] Measurement mode: SIM;

[0302] Monitored ions (m / z): 83.0.

[0303] As a result, the dodecanol concentration in Lot D was below the quantification limit, whereas the dodecanol / sodium dodecyl sulfate (mol / mol%) in Lot C was 6.2%.

[0304] From the above, it was found that the preparation Lot D produced using sodium dodecyl sulfate Lot 4 did not decompose sodium dodecyl sulfate during the storage period of 60°C and 7 days, and the solubility did not change. In contrast, the preparation Lot C produced using sodium dodecyl sulfate Lot 1 was confirmed to decompose sodium dodecyl sulfate after 60°C and 7 days of storage, and the solubility of the preparation also decreased. Therefore, it was found that a higher quality preparation can be produced by selecting sodium dodecyl sulfate of appropriate quality and producing the preparation. That is, it can be seen that in order to remove the sodium dodecyl sulfate batches such as Lot 1 that are easily decomposed and select the sodium dodecyl sulfate that is not easily decomposed such as Lot 2, the method of measuring the sulfate ion concentration detected by ion chromatography after storage for 4 days under accelerated conditions of a temperature of 70°C and a relative humidity of about 10% is effective for screening a pharmaceutical preparation raw material for manufacturing a preparation with better stability. Moreover, sodium dodecyl sulfate having a sulfate ion concentration of 1 mg / L or less measured by this method can be selected as a pharmaceutical preparation raw material for manufacturing a pharmaceutical preparation with excellent stability.

[0305] Example 7: Storage Condition Setting (Temperature) of Sodium Lauryl Sulfate

[0306] Sodium lauryl sulfate is usually stored at room temperature, but storage conditions (temperature) are set assuming that the temperature conditions may be higher than room temperature during transportation. Sodium lauryl sulfate Lot 5 (manufacture date: October 13, 2016) was used, with a plastic bag as the primary package and an aluminum bag as the secondary package, and stored according to the temperature conditions and periods shown in Table 1. After that, about 250 mg was placed in a glass vial and stored in an open system at a temperature of 70°C and a relative humidity of about 10% (LiCl saturated saline solution) for 4 days. For the sample after storage, sulfate ions generated by the decomposition of sodium lauryl sulfate were quantified according to the ion chromatography method shown in Example 4.

[0307] [Table 1]

[0308]

[0309] As a result, the sulfate ion concentration detected by ion chromatography under all the above conditions was less than 1 mg / L. Therefore, the most stringent condition 6 (45 days at 40°C and 48 hours at 60°C) was used as the upper limit of the storage condition, and the batches of sodium dodecyl sulfate that were stored without exceeding the upper limit were judged to be useful for manufacturing preparations with better stability.

[0310] Example 8: Relationship between impurities in sodium lauryl sulfate and formulation quality (dissolution)

[0311] Using multiple batches of preparations, the relationship between the amount of dodecanol detected in the preparations as an impurity of sodium dodecyl sulfate and the dissolution of the preparations was studied. Preparations of preparation batches Lot E (manufacturing date: 2016.08.24), Lot F (manufacturing date: 2016.08.29), Lot G (manufacturing date: 2016.08.24), Lot H (manufacturing date: 2016.10.19), Lot I (manufacturing date: 2016.03.29), Lot J (manufacturing date: 2016.03.24), and Lot K (manufacturing date: 2015.07.07) were placed in glass vials and stored in a closed system at a temperature of 60°C. Dissolution tests were performed on samples before storage and after storage for 7 days, and quantification of dodecanol by GC / MS was performed on samples after storage for 7 days. The dissolution test and quantification of dodecanol by GC / MS were performed according to the method shown in Example 6.

[0312] The results of the dissolution test showed that the dissolution curves of Lot H, Lot I, Lot J, and Lot K were the same as before storage. In contrast, the dissolution rates of Lot E, Lot F, and Lot G were significantly lower than before storage ( Fig. 10A In addition, the quantitative results of dodecanol in the samples after storage showed that the dodecanol / sodium dodecyl sulfate (mol / mol%) in Lot H, Lot I, Lot J, and Lot K was less than 2%, while the dodecanol / sodium dodecyl sulfate (mol / mol%) in Lot E, Lot F, and Lot G was more than 2% (Table 2).

[0313] [Table 2]

[0314] Preparation Lot Dodecanol / sodium dodecyl sulfate in the formulation after storage at 60°C for 7 days (mol / mol%) Lot E 5.0% Lot F 3.0% Lot G 2.3% Lot H 0.4% Lot I 0.8% Lot J 0.5% Lot K Below the limit of quantification

[0315] According to the decomposition mechanism of sodium dodecyl sulfate, it is believed that the dodecanol / sodium dodecyl sulfate (mol / mol%) and sulfate ion / sodium dodecyl sulfate (mol / mol%) generated by decomposition are equal. Therefore, the above results show that if the dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ion / sodium dodecyl sulfate (mol / mol%) is detected to be more than 2% in the preparation stored at 60°C in a closed system for 7 days, the dissolution of the preparation will be reduced, which will affect the quality of the preparation.

[0316] Example 9: Determination of the kinetics of decomposition of sodium lauryl sulfate in a formulation

[0317] In Example 6, it was confirmed that the decomposition rate of sodium dodecyl sulfate in the preparation differed depending on the preparation batch, and the kinetic characteristics of its decomposition were confirmed. Preparations Lot A and Lot B were used and stored in a closed system at a temperature of 60°C. According to the GC / MS dodecanol determination method shown in Example 6, for Lot A, the dodecanol was quantitatively measured in samples before storage, 4 days, 7 days, 8 days, 9 days, 12 days, and 14 days after storage, and for Lot B, the dodecanol was quantitatively measured in samples after storage for 4 days, 7 days, 8 days, 9 days, and 12 days.

[0318] The results are shown in Fig.11 It was confirmed that the time until dodecanol was detected was different between the preparations Lot A and Lot B, and that the amount of dodecanol increased rapidly after it was produced.

[0319] This is considered to reflect that sulfuric acid is generated by decomposition of sodium lauryl sulfate in the preparation, and the sulfuric acid acts as a catalyst to promote decomposition, resulting in accelerated decomposition of sodium lauryl sulfate.

[0320] Industrial Applicability

[0321] The invention is used for screening sodium dodecyl sulfate, a raw material for pharmaceutical preparations used for manufacturing drugs, or for screening, quality evaluation, and manufacturing of compositions or drugs containing sodium dodecyl sulfate.

Claims

1. A screening method, which is a screening method for pharmaceutical preparation raw materials containing sodium lauryl sulfate, characterized in that: The impurities are detected after the above-mentioned preparation raw materials are pretreated under accelerated conditions, the above-mentioned accelerated conditions are a temperature condition of 65 to 75° C. and a humidity condition of 10% RH or less, the above-mentioned impurities are sulfate ions, and when the impurities are detected by ion exchange chromatography, the pharmaceutical preparation raw materials having a sulfate ion content of 1 mg / L or less in the above-mentioned pharmaceutical preparation raw materials are screened, The pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof:

2. The method of claim 1, wherein: Pre-treat under the above accelerated conditions for more than 2 days.

3. The method of claim 1, wherein: Pre-treatment was performed under the above accelerated conditions for 4 days.

4. A screening method, which is a screening method for a pharmaceutical preparation raw material containing sodium lauryl sulfate, comprising the following steps: Step a, screening batches or packaging units of the above-mentioned preparation raw materials stored under specified conditions, the above-mentioned conditions are 30°C to 40°C, 47 days or less, or when the temperature exceeds 40°C, the cumulative time of exceeding 40°C and being below 60°C is within 48 hours, and the "storage" refers to the period from the manufacture to the use of the pharmaceutical preparation raw materials; Step b, omitting the detection of impurities in the raw materials for pharmaceutical preparations screened in the above step a, The pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof:

5. The screening method according to claim 4, wherein The above conditions are storage conditions during transportation.

6. A method for evaluating the quality of a pharmaceutical preparation containing sodium lauryl sulfate, characterized in that: A pharmaceutical preparation containing sodium dodecyl sulfate is pretreated under accelerated conditions and then tested for impurities, wherein the pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof: The above-mentioned acceleration condition is a temperature condition of 55-65° C., the above-mentioned impurities are sulfate ions, dodecanol or sodium dodecyl sulfate / dodecanol complexes, and the pharmaceutical preparations in which the above-mentioned impurities are present in the form of dodecanol / sodium dodecyl sulfate (mol / mol%) or sulfate ions / sodium dodecyl sulfate (mol / mol%) at a level of less than 2% in the above-mentioned preparations are screened.

7. The quality evaluation method according to claim 6, wherein: The impurity is dodecanol, which is detected by gas chromatography.

8. The quality evaluation method according to claim 6, wherein: The above impurities are sulfate ions, which are detected by ion exchange chromatography.

9. The quality evaluation method according to claim 6, wherein: The above pretreatment is carried out under the above accelerated conditions for more than 2 days.

10. The quality evaluation method according to any one of claims 6 to 9, wherein The above pretreatment was carried out under the above accelerated conditions for 7 days.

11. A manufacturing method, which is a manufacturing method for a pharmaceutical preparation containing sodium lauryl sulfate, comprising the following steps: Step a, pretreating sodium dodecyl sulfate as a raw material for a pharmaceutical preparation under accelerated conditions, wherein the accelerated conditions are a temperature condition of 65 to 75° C. and a humidity condition of less than 10% RH; Step b, after the pretreatment in step a, detecting impurities, and screening pharmaceutical preparation raw materials having a sulfate ion content of less than 1 mg / L as an impurity; as well as Step c, using the pharmaceutical preparation raw materials screened in the above step b to manufacture a pharmaceutical preparation, The above-mentioned pharmaceutical preparation contains a compound represented by formula (I) or a salt thereof:

Citation Information

Patent Citations

  • Novel crystal of tetracyclic compound

    WO2015163447A1

  • Amorphous form of tetracyclic compound

    WO2016021707A1

  • Production method of high-purity sodium dodecyl sulfate

    CN103058894A

  • Fuyanling expandable vaginal suppository, and preparation method and detection method thereof

    CN103520603A

  • Pharmaceutical composition containing rifampicin and sodium dodecyl sulfate

    CN103816545A